[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.48% 82.60 81.40 82.60 82.60 80.40 80.40 163,853 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.7 383

Ekf Diagnostics Share Discussion Threads

Showing 3776 to 3798 of 3950 messages
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
DateSubjectAuthorDiscuss
08/9/2021
09:48
Conviction is the enemy of truth wan. I am currently long but have this baby on a very, very short leash as this is hardly acting right. One should always get suspicious around failed attempts to break out.
tongosti
08/9/2021
07:58
Above post edited to include more of the story
wan
08/9/2021
07:27
In broader healthcare news, and as healthcare transitions to a new model of care - Amazon looks to bring telehealth, in-person care to 20 more cities. It will soon offer the "full package" of hybrid virtual/in-person care in Philadelphia, Chicago, Dallas and Boston, Insider reports, with more expansion to follow in 2022. By Kat Jercich September 07, 2021 Amazon is reportedly looking to launch its app-based home visits in 20 major U.S. cities through 2022. According to Insider's Blake Dodge, Amazon Care will bring the "full package" of telehealth and in-person services to Philadelphia, Chicago, Dallas and Boston in 2021, with 16 more to follow the next year. Amazon representatives told Healthcare IT News after publication that the company does not comment on rumors or speculation. WHY IT MATTERS Amazon Care has grown rapidly since it was first offered exclusively to the tech giant's Seattle-based employees in 2019. This past September, Amazon announced it would allow employees to access the app-based care throughout Washington state. It then made services available to other employers in the state before officially expanding its telehealth option to employers in all 50 states this summer. But its in-person services, which include follow-up blood draws and exams, have been limited so far to users in D.C. and Baltimore, as well as in Washington state. Now, reports Dodge, Amazon plans to offer in-person options in Atlanta, Denver, Detroit, Houston, Indianapolis, Kansas City, Los Angeles, Miami, Minneapolis, Nashville, New York, Phoenix, Pittsburgh, San Francisco, San Jose and St. Louis in 2022. That would bring the total number of cities up to 22, in addition to the entirety of Washington state. Dodge also notes that Amazon has been attempting to make inroads at health plans, which would open up the service to insured people in addition to employer clients. THE LARGER TREND In June, an Amazon exec said it had signed several companies to the company's telehealth service. At the time, VP Babak Parviz said the company is planning to make the "hybrid" virtual/in-person service available in additional regions "as fast as we can." Amazon also made waves in July with news of its at-home COVID-19 testing kit, which can be purchased for $39.99. Full story - hTTps://www.healthcareitnews.com/news/amazon-looks-bring-telehealth-person-care-20-more-cities Amazon's healthcare website has been updated accordingly - Experience a new kind of healthcare Amazon Care is healthcare built around you, your life, and your schedule. hTTps://amazon.care/
wan
07/9/2021
08:07
wan - Many thanks - My doc has just told me I need to get a serology test - Will feed back details of which test used after I get tested.
pugugly
07/9/2021
05:44
Pugugly...Yes, EKF have exclusive rights to market and distribute the Kantaro serology tests in the UK and Europe. Interest in this area is clearly building, and it will thus be interesting to see to what degree it might be being utilised - hTTps://www.ekfdiagnostics.com/ekf-and-kantaro-biosciences-partner-to-market-quantitative-covid-antibody-testing-in-uk-and-europe.html hTTps://www.ekfdiagnostics.com/COVID-SeroKlir.html
wan
06/9/2021
21:42
gm - your investing acumen is out of this universe. Please keep taking the bait - you're the one and only in this (online) village. Lol.
tongosti
06/9/2021
20:10
Probably not!
senseibull
06/9/2021
19:45
I cannot remember if EKF are in the business of Serological tests which are growing in importance as an aid to evaluating when and if a booster vaccination is needed. Thoughts?
pugugly
06/9/2021
17:53
your timing is usually off Tong, we've worked it out since your spectacular #SDI trade.
mg1982
06/9/2021
17:49
Price action v v poor.
tongosti
04/9/2021
16:34
You would make a song and a dance for the share price to go up though. Let's see if this baby will follow up this coming week (if not managing risk is the name of the game - unless one is called mg of course:).
tongosti
04/9/2021
07:27
Obviously we don't want to make a song and dance about it, but investors may have noted that rates of infection are on the rise again, and are unfortunately likely, at the very least, to stay elevated. The following also suggests the same, with test manufacturing and lab capacities being increased - Abbott, Quest, Quidel scramble to add test capacity as delta variant surges Published Sept. 3, 2021 The diagnostics industry is racing to add capacity as the delta-driven surge in COVID-19 cases increases demand for PCR tests and at-home rapid antigen kits. Quest Diagnostics is adding testing platforms in regions with high demand while manufacturers of at-home tests such as Abbott and Quidel are ramping up capacity again after the early summer slump. Demand for coronavirus tests plummeted over the first half of the year as the vaccine rollout brought the crisis under control in the U.S. However, since July the more transmissible delta variant has ripped through the country, most notably in areas with low vaccination rates. The nationwide seven-day average of new COVID-19 cases is now up to 167,000, more than double the level at the start of August. The commercial impact of the delta surge, and management expectations of the sustainability of the sales opportunity, will become clearer when the financial results season gets underway late next month. Full story - hTTps://www.medtechdive.com/news/abbott-quest-quidel-scramble-to-add-test-capacity-as-delta-variant-surges/606057/ Important as the above is, ultimately the bigger story here will be the new opportunities created and the positive impact delivered by EKF's Growth Strategy on the 'core' business (new and existing).
wan
03/9/2021
18:02
The thing is Tong, if you lie and hyperbolate, you keep coming across as the idiot of the village that's lost money and is desperately trying to gain it back. It's best if you just keep quiet about when you'll enter and exit the trade. It doesn't take a genius to work out when #EKF breaks out there'll be plenty of traders entering it.
mg1982
03/9/2021
15:21
Thanks for your concern darling. I am aware you don't mind holding on to a lifeless stock for years so my approach is - by definition - a bit of a stretch for you.
tongosti
03/9/2021
15:19
Mr Tong don't do it, you don't wana be holding this going into the weekend
mg1982
03/9/2021
14:16
Wow - so quiet on here. Guess too many false dawns and folks don't want to jinx it do they. Talk about taking on calculated risk - ready to beef up to a full risk position IF we start picking up steam heading into the close.
tongosti
02/9/2021
11:17
Not that convinced yet so opened up only a half risk (for my standards) position - with the view to top up IF there's a decent follow up. Tight stop makes sure one does not join the crowd if the call is wrong. PS. Sorry mg - this is as live as one gets innit
tongosti
02/9/2021
09:01
And the 'perhaps' really interesting thing, is that Amazon has been, and apparently is, testing a lot more than just its own employees.......unless you reside within New York State, as collected samples are required to have a New York State clinical laboratory permit. Amazon has submitted an application for a clinical laboratory permit which is currently under review. From my understanding though, apparently the collection kits are widely available in other US states. Unfortunately, Covid infection rates have been on the rise in the US and elsewhere (far more of my close family, relations and friends are currently contracting Covid compared to the previous waves!) - EU moves to restrict travel from US over rising Covid cases Council warns that American infection rate is well above the bloc’s safe maximum Javier Espinoza in Brussels and Kiran Stacey in Washington AUGUST 30 2021 After a rapid rollout earlier this year, US vaccinations slowed as a significant minority of people became more entrenched in their resistance to getting vaccinated. As a result, Covid cases in the US have climbed to a level not seen since January, according to an FT analysis of public data — more than three times the rate in the EU. In some states, such as Florida, more people are becoming infected every day than at any point during the pandemic. hTTps://www.ft.com/content/a3f7aebb-0284-44d0-8c72-12ccde379c6b
wan
02/9/2021
08:19
Probably more testing required as time goes on and health checks. https://www.telegraph.co.uk/business/2021/09/01/amazon-adds-thousands-uk-jobs-global-hiring-spree/ https://www.thisismoney.co.uk/money/markets/article-9948441/Amazon-create-2-000-UK-jobs-sales-boom.html
mirandaj
01/9/2021
08:12
Targeting Trends in Diabetes Testing Posted by Chris Wolski | Aug 30, 2021 | Diabetes & Metabolic Diseases Testing patients’ glycated hemoglobin or HbA1C continues to be the gold standard in clinical settings to determine if they are diabetic or have well-controlled disease. For those who are either at normal or low risk for disease, monitoring A1C twice a year is typically sufficient, and those who need more stringent monitoring or have uncontrolled disease should be monitored up to four times per year, according to Dennis Begos, MD, FACS, FACRS, associate medical director for Medical and Scientific Affairs at Nova Biomedical. “These tests all paint a picture of where the disease is at,” notes Heidi Cassaletto, senior vice president Portfolio Strategy and Global Marketing for Ortho Clinical Diagnostics. And with more home testing products coming to market and most primary care physicians using A1C as their go-to testing control, it wouldn’t be a stretch to think that diabetes testing has reached a sort of end point; what we have now is enough. However, while the experts agree that A1C and glucose testing are well established and can be effective, there’s other testing avenues that may offer better results. “There’s always a desire to find other controls,” notes Gavin Jones, global product manager for Diabetes Care at EKF Diagnostics. “Glucose monitoring doesn’t always work best.” Shane O’Neill, global director of Scientific Affairs at EKF, says that, for those patients who are tougher to monitor, glycated albumin (GA) could be the answer. “It can be harder to monitor some diabetics with A1C who have issues or treatments that affect their red blood cells (RBC),” he says. “GA levels are not affected by the life span of RBC, it is a useful substitute for A1C when the interpretation of A1C is problematic, e.g., in the presence of hemoglobinopathies, iron deficiency, and anemias.” That being said, he notes that A1C has a specific benefit “The beauty of A1C is that it is standardized across manufacturers, and has been available for decades and has been the gold standard,” he says. However, one of the limitations of A1C is that it measures a two- to three-month period of a person’s life; in other words, it isn’t as immediate. Particularly for those diabetics with chronic kidney disease (CKD), it’s also not as accurate according to research published by the NCBI2. This research points to glycated albumin as a more effective way to measure blood glucose control in patients with CKD. And with the number of people worldwide suffering from CKD, this could have significant advantages in monitoring and, more importantly, controlling disease progression. O’Neill notes that one of the other advantages of measuring glycated albumin is that it fills the gap between at-home and in-lab glucose monitoring and yearly or twice yearly A1C measurements, giving a diagnostic window of the patient’s condition over two to three weeks. He predicts that, as with A1C, glycated albumin tests will eventually become standardized across manufacturers and widely used. Full article - hTTps://clpmag.com/disease-states/diabetes-metabolic/targeting-trends-in-diabetes-testing/ Note the reference to Chronic Kidney Disease (CKD). Recently I have noticed that Renalytix has utilised, and will monitor HbA1c as part of a new clinical trial. That aside, we know EKF's HbA1c Quo-Test is being upgraded, note in the above article the reference to access - Beyond testing methodologies, gold standards, and advanced diagnostic and treatment technologies, Begos brings up a larger societal issue related to diabetes testing that needs to be addressed: access. “Screening can be a particular problem in low- and middle-income countries (LMIC), and in remote areas with poor access to laboratory testing, and point-of-care (POC) devices can be useful in these settings,” he says. For him, one of the most exciting trends related to access is the availability of POC out-of-hospital tests that can allow untrained staff to run A1C and glucose tests, helping to give access to these tests and motivating those even with access to take and even seek out testing.
wan
01/9/2021
07:37
Good to note MHC news today - Medical laboratory accreditation for COVID testing ISO 15189:2012 accreditation confirms internationally recognised gold standard for MHC lab testing MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces that it now has ISO 15189:2012 accreditation across the Company's COVID-19 testing service, a mark of confidence that the service meets internationally recognised gold standards for performance and competence. "We are delighted to now have in place accreditation across our COVID-19 testing service, which is a clear sign to our existing customers and potential new customers that our medical laboratories and operational systems are extremely rigorous and structured around best possible practice within the industry." Full release - hTTps://uk.advfn.com/stock-market/london/myhealthchecked-MHC/share-news/MyHealthChecked-PLC-Medical-laboratory-accreditati/85953515 Quality counts, and as a user of PrimeStore® MTM sample collection devices, it's also an integral part.
wan
31/8/2021
13:00
Tic toc tic tocWill it happen this time?
tongosti
30/8/2021
07:16
Edit...Correct Luke Daum linkedin link added to above post
wan
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 03:08:45